GlassScriptPhysician profile
Garrett Pennell
NPI 1710415823
$6,944.60
in general payments reported to CMS, 2019-2025
17 companies · $30.12 in 2025
The $30.12 reported for 2025 was less than what a typical Optometrist provider received nationally (typical 2025 total: $204).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,547 · 2021: $456 · 2022: $427 · 2023: $541 · 2024: $3,944 · 2025: $30.12.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,175 · Travel and Lodging: $1,340.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,174.68 |
| Travel and Lodging | $1,340.04 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Alcon Vision LLC | $2,249.31 | 2022-2025 | Clareon, Wavelight Refractive Suite, Systane |
| Johnson & Johnson Vision Care, INC. | $1,222.96 | 2019 | |
| Harrow Eye, LLC | $711.67 | 2023-2024 | Vevye, Iheezo |
| Bausch & Lomb, A Division of Bausch Health US, LLC | $653.58 | 2019-2021 | |
| Alcon Research LLC | $560.20 | 2024 | |
| Bausch & Lomb Americas INC. | $439.07 | 2022-2024 | Infuse, Ic-8 Apthera Iol, Xiidra |
| Glaukos Corporation | $346.16 | 2022-2024 | Gts100_glaukos Istent Trabecular Micro-Bypass Stent System, Istent Trabecular Micro-Bypass System Model Is3 |
| Tarsus Pharmaceuticals, INC. | $181.60 | 2024 | Xdemvy |
| Rxsight INC | $172.61 | 2022-2023 | Rxsight Light Adjustable Lens (Rxlal), Rxsight Injector Handpiece, Rxsight Light Delivery Device (Ldd) |
| Coopervision INC. | $126.38 | 2019 | |
| Ocular Therapeutix, INC. | $125.00 | 2024 | Dextenza |
| Lkc Technologies, INC. | $45.45 | 2024 | |
| Johnson & Johnson Surgical Vision, INC. | $29.53 | 2022 | |
| Oyster Point Pharma, INC. | $27.44 | 2024 | Ryzumvi, Tyrvaya |
| Biotissue Holdings INC. | $21.78 | 2022 |
Show all 17 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $20.08 | 2022 | |
| Kala Pharmaceuticals, INC. | $11.78 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Garrett Pennell listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.